Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Pierre Fabre Group
DescriptionAn oral selective dopamine D3 receptor (DRD3) antagonist and serotonin (5-HT1A) receptor partial agonist
Molecular Target Dopamine D3 receptor (DRD3) ; Serotonin (5-HT1A) receptor
Mechanism of ActionSerotonin (5-HT1A) receptor partial agonist; Dopamine D3 receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSchizophrenia
Indication DetailsTreat acute schizophrenia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today